EPS for Atossa Genetics Inc. (ATOS) Expected At $-0.07; Teucrium Commodity Trust (TAGS)’s Sentiment Is 0.29

February 18, 2018 - By Marie Mckinney

Analysts expect Atossa Genetics Inc. (NASDAQ:ATOS) to report $-0.07 EPS on March, 15.They anticipate $0.70 EPS change or 90.91% from last quarter’s $-0.77 EPS. After having $-0.17 EPS previously, Atossa Genetics Inc.’s analysts see -58.82% EPS growth. The stock decreased 9.49% or $0.066 during the last trading session, reaching $0.625. About 2.69M shares traded. Atossa Genetics Inc. (NASDAQ:ATOS) has declined 86.91% since February 18, 2017 and is downtrending. It has underperformed by 103.61% the S&P500.

The ETF increased 0.40% or $0.09 during the last trading session, reaching $22.7. About 6,019 shares traded or 2648.40% up from the average. Teucrium Agricultural ETF (TAGS) has declined 16.54% since February 18, 2017 and is downtrending. It has underperformed by 33.24% the S&P500.

Atossa Genetics Inc. a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company has market cap of $19.89 million. The firm is conducting a Phase II clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in-situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen for post-breast cancer and preventative therapy, as well as a potential therapy for breast density and other breast health conditions. It currently has negative earnings. It offers ForeCYTE Breast Aspirator and FullCYTE Breast Aspirator, which collects specimens of nipple aspirate fluid for cytological testing at a laboratory; and a transport kit to assist with the packaging and transport of NAF samples to a laboratory, as well as makes and sells various medical devices primarily consisting of tools to assist breast surgeons.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


>